Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.

被引：1
|
作者：
Heidel, F
Cortes, J
Ruecker, F
Kaufmann, M
Aulitzky, W
Letvak, L
Kindler, T
Huber, C
Dohner, H
Kantarjian, H
Fischer, T
机构：
[1] Univ Hosp Mainz, Mainz, Germany
[2] Univ Hosp Ulm, Ulm, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
[4] Novartis Pharm Corp, E Hanover, NJ USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1853.1853
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1853
引用
收藏
页码：527A / 527A
页数：1
相关论文
共 50 条
  • [41] Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)
    Zeidner, Joshua F.
    Montiel-Esparza, Raul
    Knaus, Hanna A.
    Berglund, Sofia
    Zeidan, Amer M.
    McCurdy, Shannon R.
    Prince, Gabrielle T.
    Gondek, Lukasz P.
    Ghiaur, Gabriel
    Showel, Margaret M.
    DeZern, Amy E.
    Pratz, Keith W.
    Smith, B. Douglas
    Levis, Mark J.
    Foster, Matthew C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik W.
    Streicher, Howard
    Karp, Judith E.
    Luznik, Leo
    Gojo, Ivana
    BLOOD, 2016, 128 (22)
  • [42] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 903 - 903
  • [43] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [45] HIGH-DOSE CYTOSINE-ARABINOSIDE (ARA-C) IN INDUCTION PROLONGS REMISSION IN ACUTE MYELOID-LEUKEMIA (AML) - UPDATED RESULTS OF A RANDOMIZED PHASE-III TRIAL
    BISHOP, JF
    MATTHEWS, JP
    YOUNG, GA
    SZER, J
    GILLETT, A
    JOSHUA, D
    BRADSTOCK, K
    ENNO, A
    WOLF, M
    FOX, R
    COBCROFT, R
    HERRMANN, R
    VANDERWEYDEN, M
    JUNEJA, S
    BLOOD, 1994, 84 (10) : A232 - A232
  • [46] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
    Brunner, Andrew
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottman, Oliver
    Xu, Siyan
    Sun, Haiying
    Naidu, Purushotham
    Szpakowski, Sebastian
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael
    Wei, Andrew
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
  • [47] A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Erba, Harry Paul
    Sobecks, Ronald
    Advani, Anjali
    Nichols, Julie
    Chan, Josephine
    Kalaycio, Matt
    BLOOD, 2006, 108 (11) : 754A - 754A
  • [48] A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
    Chevallier, Patrice
    Hunault-Berger, Mathilde
    Larosa, Fabrice
    Dauriac, Charles
    Garand, Richard
    Harousseau, Jean-Luc
    LEUKEMIA RESEARCH, 2009, 33 (08) : 1124 - 1126
  • [49] Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML)
    Kashani, F. Ravandi
    Cortes, J.
    Faderl, S.
    Jones, D.
    Byrd, A.
    Brandt, M.
    Garcia-Manero, G.
    Levis, M.
    Andreeff, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
    R. Willemze
    S. Suciu
    P. Muus
    C. J. M. Halkes
    G. Meloni
    L. Meert
    M. Karrasch
    J. Rapion
    M. Vignetti
    S. Amadori
    T. de Witte
    J. P. Marie
    Annals of Hematology, 2014, 93 : 965 - 975
12345